Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement

Drittmittelfinanzierte Einzelförderung


Details zum Projekt

Projektleiter/in:
Prof. Dr. Björn Eskofier
Dr.-Ing. Felix Kluge

Projektbeteiligte:
Dr.-Ing. Felix Kluge
Arne Küderle
Martin Ullrich

Beteiligte FAU-Organisationseinheiten:
Lehrstuhl für Informatik 14 (Maschinelles Lernen und Datenanalytik)

Mittelgeber: Europäische Union (EU) (1.1.51 - Sonstige)
Akronym: MOBILISE-D
Projektstart: 01.04.2019
Projektende: 31.03.2024


Abstract (fachliche Beschreibung):

Optimal treatment of the impaired mobility resulting from ageing and chronic disease is one of the 21st century's greatest challenges facing patients, society, governments, healthcare services, and science. New interventions are a key focus. However, to accelerate their development, we need better ways to detect and measure mobility loss. Digital technology, including body worn sensors, has the potential to revolutionise mobility assessment. The overarching objectives of MOBILISE-D are threefold: to deliver a valid solution (consisting of sensor, algorithms, data analytics, outcomes) for real-world digital mobility assessment; to validate digital outcomes in predicting clinical outcome in chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, proximal femoral fracture recovery and congestive heart failure; and, to obtain key regulatory and health stakeholder approval for digital mobility assessment. The objectives address the call directly by linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice. MOBILISE-D consists of 35 partners from 13 countries with long, successful collaboration, combining the requisite expertise to address the technical and clinical challenges. To achieve the objectives, partners will jointly develop and implement a digital mobility assessment solution to demonstrate that real-world digital mobility outcomes can successfully predict relevant clinical outcomes and provide a better, safer and quicker way to arrive at the development of innovative medicines. MOBILISE-D's results will directly facilitate drug development, and establish the roadmap for clinical implementation of new, complementary tools to identify, stratify and monitor disability, so enabling widespread, cost-effective access to optimal clinical mobility management through personalised healthcare.


Zuletzt aktualisiert 2019-15-04 um 12:13